Revvity to Present at J.P. Morgan Healthcare Conference
Ticker: RVTY · Form: 8-K · Filed: Jan 9, 2024 · CIK: 31791
Complexity: simple
Sentiment: neutral
Topics: conference, investor-relations, corporate-event
TL;DR
**Revvity is presenting at a major healthcare conference, watch for potential stock movement.**
AI Summary
Revvity, Inc. filed an 8-K on January 9, 2024, to announce that it will be participating in the 42nd Annual J.P. Morgan Healthcare Conference. This is a significant event where the company will present its business strategy and financial outlook to investors and analysts. For shareholders, this matters because the presentation could influence the stock price based on the information shared and the market's reaction to Revvity's future plans and performance expectations.
Why It Matters
This filing signals an upcoming event where Revvity will communicate directly with the investment community, potentially impacting investor sentiment and stock valuation based on new disclosures or reaffirmed guidance.
Risk Assessment
Risk Level: low — This filing is a routine announcement of a conference presentation and does not inherently carry significant risk.
Analyst Insight
A smart investor would monitor news and transcripts from the J.P. Morgan Healthcare Conference for any new information or guidance provided by Revvity, as this could influence future stock performance.
Key Players & Entities
- Revvity, Inc. (company) — the registrant filing the 8-K
- J.P. Morgan Healthcare Conference (event) — where Revvity will present
- January 9, 2024 (date) — date of earliest event reported
Forward-Looking Statements
- Revvity's stock price will experience increased volatility around the J.P. Morgan Healthcare Conference. (Revvity, Inc.) — medium confidence, target: January 2024
- The company will provide updates on its strategic initiatives or financial guidance during the conference presentation. (Revvity, Inc.) — high confidence, target: January 2024
FAQ
What is the purpose of Revvity, Inc.'s 8-K filing on January 9, 2024?
The 8-K filing on January 9, 2024, by Revvity, Inc. is to report the date of the earliest event, which is January 9, 2024, and to disclose information under Item 8.01, 'Other Events,' regarding their participation in the 42nd Annual J.P. Morgan Healthcare Conference.
Which specific conference will Revvity, Inc. be attending as mentioned in the filing?
Revvity, Inc. will be attending the 42nd Annual J.P. Morgan Healthcare Conference, as stated in the filing.
What is Revvity, Inc.'s business address according to the filing?
Revvity, Inc.'s business address is 940 Winter Street, Waltham, Massachusetts 02451, as listed in the filing.
What is the company's former name mentioned in the filing?
One of the company's former names mentioned in the filing is PERKINELMER INC, with a date of name change on 19991103.
What is the Registrant's telephone number?
The Registrant's telephone number, including area code, is (781) 663-6900, as provided in the filing.
Filing Stats: 665 words · 3 min read · ~2 pages · Grade level 9.6 · Accepted 2024-01-09 08:05:29
Key Financial Figures
- $1 — ange on which registered Common stock, $1 par value per share RVTY The New Yo
Filing Documents
- a53878895.htm (8-K) — 32KB
- a53878895ex99_1.htm (EX-99.1) — 28KB
- a53878895ex99_2.htm (EX-99.2) — 26KB
- a53878895ex99_2slide1.jpg (GRAPHIC) — 89KB
- a53878895ex99_2slide2.jpg (GRAPHIC) — 230KB
- a53878895ex99_2slide3.jpg (GRAPHIC) — 124KB
- a53878895ex99_2slide4.jpg (GRAPHIC) — 139KB
- a53878895ex99_2slide5.jpg (GRAPHIC) — 171KB
- a53878895ex99_2slide6.jpg (GRAPHIC) — 171KB
- a53878895ex99_2slide7.jpg (GRAPHIC) — 145KB
- a53878895ex99_2slide8.jpg (GRAPHIC) — 54KB
- a53878895ex99_2slide9.jpg (GRAPHIC) — 95KB
- a53878895ex99_2slide10.jpg (GRAPHIC) — 162KB
- a53878895ex99_2slide11.jpg (GRAPHIC) — 177KB
- a53878895ex99_2slide12.jpg (GRAPHIC) — 187KB
- a53878895ex99_2slide13.jpg (GRAPHIC) — 141KB
- a53878895ex99_2slide14.jpg (GRAPHIC) — 47KB
- a53878895ex99_2slide15.jpg (GRAPHIC) — 142KB
- a53878895ex99_2slide16.jpg (GRAPHIC) — 124KB
- a53878895ex99_2slide17.jpg (GRAPHIC) — 22KB
- 0001157523-24-000035.txt ( ) — 3331KB
- pki-20240109.xsd (EX-101.SCH) — 4KB
- pki-20240109_def.xml (EX-101.DEF) — 17KB
- pki-20240109_lab.xml (EX-101.LAB) — 26KB
- pki-20240109_pre.xml (EX-101.PRE) — 19KB
- a53878895_htm.xml (XML) — 6KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition On January 9, 2024, Revvity, Inc. (the "Company") announced preliminary expectations with respect to certain financial results for the fourth quarter ended December 31, 2023 and announced that the Company will release its fourth quarter and full year 2023 financial results on February 1, 2024. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure On January 9, 2024, Dr. Prahlad Singh, President and Chief Executive Officer of the Company, is scheduled to make a presentation to the 42 nd Annual J. P. Morgan Healthcare Conference. A copy of the presentation materials is furnished as Exhibit 99.2 to this Current Report on Form 8-K. The information in this Form 8-K (including Exhibit 99.1 and Exhibit 99.2) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits (d) Exhibits EXHIBIT INDEX Exhibit No. Description 99.1 * Press Release entitled "Revvity to Hold Earnings Call on Thursday, February 1, 2024; Provides Update on Financial Performance", issued by Revvity, Inc. on January 9, 2024. 99.2 * Revvity, Inc. Presentation to the 42 nd Annual J.P. Morgan Healthcare Conference, January 9, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL) * The exhibits relating to Item 2.02 and 7.01 shall be deemed to be furnished, and not filed. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REVVITY, INC. Date: January 9, 2024 By: /s/ Maxwell Krakowiak Maxwell Krakowiak Senior Vice President and Chief Financial Officer